This article first appeared on BostInno.

With $50 million in its pocket, biomedical software startup BostonGene, based in Waltham, is ready to take on the world of cancer treatment. The goal is to help physicians prescribe the right treatments for individual patients based on its cloud-based information and analytics software.

As Andrew Feinberg, BostonGene’s president and CEO, explains it, the company’s software essentially sequences both DNA and RNA through a patented process, allowing physicians…

Boston Biz Journal